Storia in 2 fonti

Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr

Strides Pharma divests majority stake in Pivot Path for ₹100 crore, retaining 19.95% and enabling growth through strategic investment.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo1 mese fa

Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr

Strides Pharma divests Pivot Path to Ascent Capital for ₹100 crore (₹230 crore post-money valuation). Pharma consolidating AI-driven compliance and digital transformation outsourcing; Pivot Path's 400+ SMEs and Agentic-AI target regulated sectors' market demand.

originale

economictimes.indiatimes.com1 mese fa

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth…

Timeline cronologica

sabato 27 giugno 2026·economictimes.indiatimes.com
Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore
Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move…
domenica 28 giugno 2026·thehindubusinessline.com
Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr
Strides Pharma divests majority stake in Pivot Path for ₹100 crore, retaining 19.95% and enabling growth through strategic investment.